Surrogate markers for neurological outcome in children after deep hypothermic circulatory arrest

Scott D Markowitz1, Rebecca N Ichord, Gil Wernovsky

  • 1Department of Anesthesiology and Critical Care Medicine, The Children's Hospital of Philadelphia, Pennsylvania 19104, USA. markowitzs@email.chop.edu

Insights

Neurodevelopmental disabilities affect up to 50% of children with complex congenital heart disease (CHD). Identifying mechanisms and surrogate markers for these outcomes is crucial for developing effective neuroprotective interventions.

Area of Science:

  • Pediatric Cardiology
  • Neurodevelopmental Science
  • Medical Imaging

Background:

  • Improved survival in infants with congenital heart disease (CHD) has shifted focus to neurodevelopmental morbidities.
  • Neurologic injury in complex CHD patients can stem from various factors including genetic, hemodynamic, and prenatal issues.
  • Subtle neurological deficits may manifest later in childhood, impacting speech, motor skills, and attention.

Purpose of the Study:

  • To identify mechanisms underlying neurodevelopmental injuries in children with complex CHD.
  • To evaluate surrogate markers for predicting long-term neurodevelopmental outcomes.
  • To summarize current advancements and future directions in neuroprotection for CHD patients.

Main Methods:

  • Review of existing literature on neurodevelopmental outcomes in CHD.
  • Exploration of potential surrogate markers such as serologic proteins, seizures, MRI findings, cerebral oxygenation, and neurologic examination.
  • Highlighting the potential of advanced MRI techniques and near-infrared spectroscopy.

Main Results:

  • Up to 50% of complex CHD patients exhibit speech, motor, or attention deficits by school age.
  • Current methods for identifying subtle, long-term neurological injury are limited.
  • The evaluation of surrogate markers is in its early stages due to the long-term nature of outcomes.

Conclusions:

  • There is a critical need to identify injury mechanisms for effective neuroprotection in CHD.
  • Advanced imaging and physiological measures show promise for future research.
  • Significant work remains to ensure comparable neurodevelopmental outcomes for CHD patients and their healthy peers.

Related Concept Videos